Insights
Insights From Our Experts
Articles
Brand Planning – Fitting Financial and Copay Services into Existing Models
EVERSANA’s Kevin O’Meara, Vice President, Patient Services Solutions, Joe Bachstadt, Vice President, Patient Services Affordability, and Chris Lagoerio, Director, Revenue Management, presented a session, “Brand Planning – Fitting Financial and Copay Services into Existing Models,” at…
Digital-First Future and the “Data Flywheel”: How Can Pharma Use the Combination of Data, AI, and Content to Drive Successful Product Launches
In this episode of Pharma Launch Secrets, Bozidar Jovicevic, CEO of Evermed, is joined by Scott Snyder, Chief Digital Officer at EVERSANA to discuss: What is the best way to orchestrate personalized digital experiences for HCPs…
David and Goliath: How Can First-Time Launchers Avoid Failure and Beat Big Pharma Launches
A first-time pharma launch sounds exciting……but it’s demanding. Not everybody can handle it. Want to learn how to succeed? In this episode of Pharma Launch Secrets, podcast host Bozidar Jovicevic, CEO of Evermed, is joined by…
Accelerate Patient Therapy Adoption by Eliminating Obstructive Pain Points and Waiting Games
Acquiring all the necessary information to initiate patients’ treatment can sometimes feel like a bad game of Telephone to HCPs and their staff. Missing or inaccurate details that can require multiple phone calls, emails or faxes to…
Evolution of Digital Apps to Total Wellness Solutions
Content for this article was contributed by EVERSANA’s Asia Pacific consulting practice. There is a remorseless demographic logic to increasing health costs. Life expectancy increases, the population ages, and “lifestyle” diseases penetrate further and earlier. How…
Developing Best-in-class Copay Programs for Gross-to-Net
Importance of Copay Assistance Programs A copay assistance program is an invaluable strategic cost-saving tool that biopharmaceutical companies integrate into their patient services offering. These programs are used to support a brand’s value proposition, while offsetting…
Benchmarking Your Specialty Brand’s Rx Pull-Through Against Competitors in and Out of Your Network
As an executive at a specialty drug manufacturer, you know having access to your brand’s pull-through key performance indicators (KPIs) inside your network is only a very small part of a much bigger picture. In order…
The Evolution of HTA and Its Impact on Drug Prices in Japan
Health Technology Assessment Status in Japan Health technology assessments (HTAs) are increasingly used worldwide to assess the clinical and economic impact of drug treatments and technologies, inform health policy, and guide drug pricing and reimbursement. In…
Elevate Your Brand to New Heights by Utilizing National Account Managers’ Singular Skills, Resources and Experience in an Ever-changing Marketplace
Launching new therapies is a vast undertaking for any pharmaceutical company. Setting up a product for success requires a great deal of expense, research, strategic planning and effective collaboration, just to name a few essential elements. EVERSANA’s National…
Against the Odds: Managing the Uncertainty of FDA Approval for Emerging Companies
47% of FDA applications are delayed for resourceful larger pharma. The situation is even worse for emerging pharma, with 78% of FDA applications being delayed. Pharmaceutical companies have seen a steady and daunting rise in…